- Home
- BCRX vs STOK Comparison
BCRX vs STOK Comparison
Compare BCRX & STOK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCRX
- STOK
- Stock Information
- Founded
- BCRX 1986
- STOK 2014
- Country
- BCRX United States
- STOK United States
- Employees
- BCRX N/A
- STOK N/A
- Industry
- BCRX Biotechnology: Biological Products (No Diagnostic Substances)
- STOK Biotechnology: Pharmaceutical Preparations
- Sector
- BCRX Health Care
- STOK Health Care
- Exchange
- BCRX Nasdaq
- STOK Nasdaq
- Market Cap
- BCRX 1.4B
- STOK 1.3B
- IPO Year
- BCRX 1994
- STOK 2019
- Fundamental
- Price
- BCRX $7.31
- STOK $31.41
- Analyst Decision
- BCRX Strong Buy
- STOK Strong Buy
- Analyst Count
- BCRX 11
- STOK 7
- Target Price
- BCRX $19.55
- STOK $30.83
- AVG Volume (30 Days)
- BCRX 7.0M
- STOK 1.4M
- Earning Date
- BCRX 11-03-2025
- STOK 11-12-2025
- Dividend Yield
- BCRX N/A
- STOK N/A
- EPS Growth
- BCRX N/A
- STOK N/A
- EPS
- BCRX N/A
- STOK 0.91
- Revenue
- BCRX $557,506,000.00
- STOK $199,893,000.00
- Revenue This Year
- BCRX $41.57
- STOK $416.54
- Revenue Next Year
- BCRX $6.25
- STOK N/A
- P/E Ratio
- BCRX N/A
- STOK $34.59
- Revenue Growth
- BCRX 45.85
- STOK 1218.82
- 52 Week Low
- BCRX $6.00
- STOK $5.35
- 52 Week High
- BCRX $11.31
- STOK $38.69
- Technical
- Relative Strength Index (RSI)
- BCRX 51.20
- STOK 58.45
- Support Level
- BCRX $6.44
- STOK $31.30
- Resistance Level
- BCRX $6.92
- STOK $33.88
- Average True Range (ATR)
- BCRX 0.30
- STOK 2.51
- MACD
- BCRX 0.09
- STOK -0.54
- Stochastic Oscillator
- BCRX 95.62
- STOK 29.45
About BCRX BioCryst Pharmaceuticals Inc.
BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.
About STOK Stoke Therapeutics Inc.
Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.